Stifel analyst Alex Thompson raised the firm’s price target on Dianthus (DNTH) to $65 from $52 and keeps a Buy rating on the shares following the positive Phase 2 MaGic trial in AChR+ Myasthenia Gravis. Following the data, the firm’s model now reflects higher MG odds of success of 75%, up from a prior 50% forecast, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH: